{"id":"NCT05422365","sponsor":"Biopharma Plasma LLC","briefTitle":"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults","officialTitle":"Open, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of Bioven, Manufactured by Biopharma Plasma LLC, in Adult Patients With Chronic Primary Immune Thrombocytopenia (ITP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-07-26","primaryCompletion":"2023-12-14","completion":"2023-12-14","firstPosted":"2022-06-16","resultsPosted":"2024-09-23","lastUpdate":"2024-09-23"},"enrollment":32,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immune Thrombocytopenia"],"interventions":[{"type":"DRUG","name":"Intravenous immunoglobulin (IVIG), 10% solution for infusion","otherNames":["Bioven, 10% solution for infusion"]}],"arms":[{"label":"Main Group","type":"EXPERIMENTAL"}],"summary":"The study will involve patients with chronic immune thrombocytopenia. This disease is diagnosed in the presence of isolated thrombocytopenia (decrease in platelet count only), except for other reasons. The addition of \"chronic\" means that the disease lasts more than 12 months.\n\nPatients included in the study will receive Bioven, 10% solution for infusion according to the protocol for the use of IVIG in ITP - at a dose of 0.8-1.0 g / kg 1 time per day for 2 consecutive days, the course dose of 1.6-2.0 g / kg according to the \"Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIG)\", rev. 3, 28 June 2018. After administration of the investigational drug, patients will be under medical supervision for 28 days.\n\nThe stay of patients in the study - at least 4 weeks.","primaryOutcome":{"measure":"Part (Percent) of Patients With Response (R)","timeFrame":"28 days after first administration of the study drug","effectByArm":[{"arm":"Main Group","deltaMin":24,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":35},"locations":{"siteCount":12,"countries":["Ukraine"]},"refs":{"pmids":[],"seeAlso":["https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-rev-4_en.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":32},"commonTop":["Headache","Allergic reaction"]}}